Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis
article
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This petal study evaluated the safety, tolerability, and effectiveness of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, in patients with endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (6)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Entwicklung oraler nichtpeptidischer GnRH-Antagonisten 2020
- Overview of elagolix for the treatment of endometriosis 2016
- Elagolix, a Novel, Orally Bioavailable GnRH Antagonist under Investigation for the Treatment of Endometriosis-Related Pain 2015
- Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density 2014
- Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study 2013
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK